Actavis working to add Allergan CEO Pyott to board: Reuters

Allergan CEO David Pyott

Back in November, Actavis ($ACT) said it would invite two members of Allergan's ($AGN) board to join the ranks of the new company's directors in the wake of their $66 billion merger. And according to Reuters' sources, Allergan CEO David Pyott is one of them. The Dublin drugmaker's chief, Brent Saunders, is trying to recruit Pyott to join the board, and he's currently working through corporate governance issues, the news service says. In the mean time, the two companies are working on their integration, which is going "the best of any I've been involved in," Saunders told an audience this week at the JP Morgan Healthcare Conference. Story | More

Suggested Articles

Turns out Procter & Gamble didn’t want Pfizer’s consumer health unit after all. But it did want Merck KGaA’s.

Private equity firm, in exclusive talks with Sanofi, says it'll invest to pump up Zentiva into an "independent European generics leader."

With suitor Takeda circling Shire, the Dublin-based target has pulled off a deal of its own.